Amgen’s Otezla shows positive action in mild psoriasis

Amgen (AMGN +0.4%) announces positive results from a Phase 3 clinical trial, ADVANCE, evaluating Otezla (apremilast) in patients with mild-to-moderate plaque psoriasis.

The study met the primary endpoint demonstrating a statistically significant proportion of treated patients achieving clear or almost clear skin at week 16 versus placebo. Key secondary endpoints were also met.

Detailed results will be submitted for presentation at an upcoming medical conference.

The FDA approved the PDE4 inhibitor in September 2014 for patients with moderate-to-severe plaque psoriasis.

https://seekingalpha.com/news/3570077-amgens-otezla-shows-positive-action-in-mild-psoriasis